Canopy Growth: Canaccord Downgrades To Hold, Raises Price Target To $32

Yesterday, Canopy Growth Corp (TSX: WEED) (NASDAQ: CGC) reported their third fiscal quarter results. They recorded net revenues of $152.5 million and a net loss of $829.3 million. The company managed to grow cannabis revenues 9% year over year, while other revenue grew by 61% and total revenue grew by 23%.

Canopy currently has 17 analysts covering the company with a weighted 12-month price target of C$42.89. This is up from the average before the results, which was C$28.27. One analyst has a strong buy rating. Two analysts have by ratings. Eleven analysts have hold ratings, one analyst has a sell rating, and two analysts have strong sell ratings on Canopy.

Here’s a summary of Canopy’s recent analyst changes:

  • Stifel raises target price to C$21 from C$18
  • Benchmark cuts to hold from buy
  • MKM Partners raises fair value to C$55 from C$28
  • Cowen and Company raises target price to C$75 from C$38
  • CIBC raises price target to C$64 from C$32
  • Alliance Global Partners raises target price to C$60 from C$41
  • Cormark Securities cuts to reduce from market perform

In a rare circumstance, Canaccord’s analyst Matt Bottomley downgraded Canopy and raised his 12-month price target. Bottomley downgraded Canopy to a hold from a buy rating while his price target increased to C$32 from C$25 and headlined, “In-line quarter while valuation runs above fundamental support.”

He notes the recent and ongoing run in cannabis is due to macro headlines coming out of the U.S. and says it, “has resulted in a disproportionate amount of capital to flow into a number of leading Cdn L.P.s (perhaps due to their U.S. listings where many U.S. domiciled operators are still not permitted to trade).”

Canopy’s C$152.2 million total net revenue was slightly ahead of Canaccord’s C$150.7 million. The core driver of the companies growth was the other segment, which includes Storz & Bickel vaporizers, BioSteel products, and ThisWorks health and wellness products.

Gross margin came in at 16%, down 3% from the last quarter, below Canaccord’s 22% estimate. This is primarily due to restructuring charges booked during this quarter. Bottomley calls Canopy’s -C$68.4 million EBITDA loss “lofty” and says that the annualized free cash flow burn is now at C$540 million.

Below you can see Canaccord’s third-quarter estimates vs. actual results.

Bottomley says the reasoning for the downgrade and raised price target is primarily due to “the implied negative return vs. current CGC levels,” and Canopy’s C$23.5 billion market cap, “represents ~31x NTM net revenue and 2.4x our peak revenue forecasts for the Cdn industry as a whole.”

Below you can see Canaccord’s updated the fiscal year 2021 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

The Goal is Gold Production as Soon as Possible! | Gordon Robb – ESGOLD Corp.

Snowline Gold: The Multi Billion Dollar Valley PEA

Euro Sun: Rovina Copper-Gold Project Secures Some Major Funding

Recommended

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Related News

Canopy Growth Drops Ownership In Canopy Rivers, Increases Stake In TerrAscend, Vert Mirabel

Canopy Growth (TSX: WEED) (NASDAQ: CGC) this morning announced a plan of arrangement related to...

Monday, December 21, 2020, 09:29:47 AM

Cresco Labs: Canaccord Bumps Price Target Up To $20.50

Wednesday, Canaccord came out with their updated valuations for the large three multi-state operators. With...

Sunday, January 17, 2021, 01:41:00 PM

Barrick Gold Sees Canaccord Lower Price Target On High CAPEX Spend

Last Friday Barrick Gold Corp. (TSX: ABX) had its investor day with sell-side analysts and...

Wednesday, November 23, 2022, 07:24:00 AM

Raymond James Reiterates $6 Price Target On Organigram Holdings

On April 6th, Organigram Holdings (TSX: OGI) (NASDAQ: OGI) announced that they acquired cannabis 2.0...

Thursday, April 8, 2021, 10:37:00 AM

MicroStrategy: Canaccord Lowers Price Target To $780

MicroStrategy (NASDAQ: MSTR) reported its second quarter financial results on July 29. The company reported...

Tuesday, August 3, 2021, 11:35:00 AM